Related references
Note: Only part of the references are listed.
Correction
Clinical Neurology
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (May, 10.1007/s13311-022-01237-4, 2022)
Michael Benatar et al.
NEUROTHERAPEUTICS (2022)
Article
Medicine, General & Internal
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Timothy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Share Paper
